The interaction between moxifloxacin hydrochloride (MOXH) and human serum albumin (HSA) was experimentally and simulatively investigated. Fluorescence quenching presented that MOXH bound to HSA via a static process, resulting in the formation of MOXH-HSA complex. This quenching mechanism was further verified by time-resolved fluorescence. Binding constants (K a ) of the complex were found to be 10 5 L mol À1 according to fluorescence data, and the calculated thermodynamic parameters indicated that hydrogen bonds and van der Waals force played key roles in the binding process. The UV-vis absorption, synchronous fluorescence, three-dimensional fluorescence, and circular dichroism spectra suggested that binding with MOXH induced the conformational changes on HSA; the hydrophobicity around tryptophan residues increased, the a-helix content increased, whereas the b-sheet and turn content of HSA decreased. Displacement experiments demonstrated that MOXH mainly bound to site I of HSA. Molecular docking results supported the active site and showed that the diazabicyclo of MOXH inserted into the hydrophobic pocket of HSA. Molecular dynamics simulation further ascertained that MOXH steadily bound to site I of HSA. In conclusion, hydrogen bonds and VDW force played major roles in stabilizing the MOXH-HSA complex, and hydrophobic force was also involved in the binding process.
Introduction
Moxioxacin hydrochloride (MOXH) is a novel fourthgeneration quinolone antimicrobial drug with fewer side effects and an extended half-life. Compared with older uo-roquinolones, MOXH has enhanced activity against Grampositive and atypical bacteria, while retaining Gram-negative activity.
1,2 Several studies have shown that MOXH can treat bacterial conjunctivitis and a wide variety of bacterial infections including pneumonia, sinusitis, and worsening of chronic bronchitis.
1,3-5 Furthermore, it has been widely used in the treatment and prevention of veterinary diseases in animals intended for human consumption and commercially farmed sh. 6 Studies on the interaction between drugs and biological macromolecules can provide a proper understanding of the absorption, transportation, distribution, metabolism, excretion properties and possible mechanism of drugs, thereby are benecial to design, modify and screen drug molecules. 7, 8 Previously, the interactions of MOXH with biological macromolecules including calf thymus DNA 2,9 and bovine hemoglobin 3 have been investigated by uorescence spectroscopy. These studies indicated that MOXH could bind to the two biological macromolecules through a static process and affect their structures via different combination types. Thus, the binding of MOXH to biological macromolecules may inuence the function of macromolecules and the drug efficacy. However, to our knowledge, a comprehensive study on the interaction between MOXH and the major protein in the human blood circulation remains unclear. Among these proteins, human serum albumin (HSA) is the most abundant in blood plasma. HSA regulates the transportation of various drugs and helps maintain the osmotic pressure of blood. 10, 11 Drug-HSA interaction plays a signicant role in understanding the pharmacokinetics and pharmacological effects of drugs. 12, 13 Hence, pharmacokinetic studies should be conducted in order to ascertain MOXH's presence in the blood plasma, especially with regards to its transportation and distribution properties in the circulatory system aer oral administration.
In the present study, attempts were conducted to assess the binding process of MOXH with HSA by employing multispectroscopic techniques including uorescence, time-resolved uorescence, UV-vis absorption spectroscopy, and circular dichroism spectroscopy. The binding information such as quenching mechanism, binding parameters, acting forces, binding mode and conformational changes were discussed. Moreover, molecular docking and dynamics simulations were applied to evaluate the dynamics and stability of the MOXH-HSA complex, and to corroborate the results obtained from spectroscopy studies.
Experimental

Materials
MOXH (99% purity) was purchased from Yitai Technology Co. (Shanghai, China). Fatty-acid-free HSA (A1887-5G) was acquired from Sigma Aldrich (St. Louis, MO, USA). Phenylbutazone and ibuprofen were purchased from J&K Scientic Ltd. (Beijing, China). The stock solution of HSA was prepared at 2.0 Â 10 À5 mol L À1 in phosphate buffer solution (PBS, pH ¼ 7.4).
MOXH stock solution was prepared at a concentration of 2.0 Â 10 À4 mol L À1 with PBS. All solutions were diluted to the required volume with PBS prepared by triple-distilled water. All stock solutions were stored at 0-4 C.
Fluorescence spectroscopy measurements
Fluorescence analysis was executed on a Cary Eclipse uores-cence spectrophotometer (Varian, CA, USA) equipped with 1.0 cm quartz cells. The HSA concentration was xed at 2.0 Â 10 À6 mol L À1 while the MOXH concentrations varied from 0 to
Prior to uorescence measurements, samples were thermally equilibrated at 298 K, 304 K, and 310 K for about 30 min. An excitation wavelength of 280 nm was employed, and the emission spectra were recorded from 290 nm to 450 nm. The widths of excitation and emission slits were set at 5 and 10 nm, respectively. To eliminate inner lter effect, uorescence intensities were corrected based on the following formula:
where F corr and F obs are the corrected and measured uores-cence intensities, respectively; A ex and A em are the absorbance values at excitation and emission wavelengths, respectively. Synchronous uorescence spectra of HSA with various MOXH concentrations were recorded in the wavelength range of 200-400 nm at 298 K. The excitation and emission wavelength interval (Dl) were set at 15 and 60 nm, respectively.
Three-dimensional (3D) uorescence spectra of HSA (2.0 Â 10 À6 mol L À1 ) and the HSA-MOXH mixture solution (molar ratio, 1 : 1) were obtained at the excitation wavelength range from 200 to 400 nm with 5 nm increments. The emission spectra were monitored between 200 and 500 nm. and were calculated using the following equation:
where C p is the molar concentration of the protein, n is the number of amino acid residues, and l is the path length.
Site marker displacement studies
Displacement experiments were conducted using the site markers, phenylbutazone and ibuprofen. The molar ratio of MOXH to HSA was maintained at 1 :
. The binary MOXH-HSA solutions were vortexmixed and incubation for 30 min. Then, the phenylbutazone and ibuprofen solutions with varied concentrations were gradually added and incubated for another 30 min. Fluorescence spectra were recorded at 298 K under the same experimental conditions as previously described.
Molecular docking
Binding mode of the ligand with HSA was examined by molecular docking using the FlexX program 16 interfaced within LeadIT. The 3D structure of MOXH and HSA were downloaded from PubChem (PubChem CID: 152946) and RCSB protein data bank (PDB: 1H9Z), respectively. A global docking including all amino acid residues of HSA was performed. Correct tautomers and protonation states were assigned, and hydrogen atoms were added to the binding site residues using the receptor wizard. The FlexX hybrid algorithm (enthalpy and entropy driven ligand binding), as available in LeadIT, 17 was used to place the "base fragment". Other parameters were set at their default values.
Molecular dynamics (MD) simulations
MD simulations were conducted with YASARA v17.4.17, 18 using the AMBER14 force eld. 19 Partial atomic charges of ligand were computed using the AM1-BCC model 20 implemented in YASARA. MD simulations in explicit water were performed at a constant temperature (298.15 K) aer initial energy minimization procedures. Periodic boundary conditions were applied to system, and counter ions were randomly added by replacing water molecules with Na or Cl to provide a charge-neutral system. Longrange Coulomb interactions were included using particle-mesh Ewald (PME) summation and a cut-off of 8.0Å. Simulations were carried out in their entirety, employing a pre-dened macro (md run) within the YASARA package. Multiple time steps were used in the simulation: 1.25 fs for intramolecular and 2.5 fs for intermolecular forces, and data were collected every 100 ps. The two-dimensional maSp of interaction were calculated using LigPlot program. 
Results and discussion
Quenching mechanism
Fluorescence spectroscopy is widely used to study drug-protein interactions due to its exceptional sensitivity, selectivity, convenience, and abundance of theoretical foundation. 22 The effect of MOXH on the uorescence intensity of HSA at 298 K was displayed in Fig. 1(a) . HSA generated an obvious uores-cence emission band at 337 nm, which was gradually quenched with increasing MOXH concentrations. In addition, MOXH alone did not emit uorescence at the highest concentration. Therefore, such a decrease in intensity can be ascribed to the quenching of HSA by MOXH.
The quenching mechanism is frequently categorized into dynamic quenching, static quenching, or a combination of both two, which can be distinguished by their differential dependence on temperature. 23 Given that dynamic quenching depends on diffusion and high temperatures to achieve larger diffusion coefficients, the quenching constant should increase with temperature risen. However, the effect is typically reversed in static quenching. That is, increased temperatures are likely to decrease the quenching constant because of the stability of ground state complexes were affected by temperature. 24, 25 To explore the quenching mechanism qualitatively, the uorescence data at different temperatures were analyzed using the Stern-Volmer equation: 
where F 0 and F are the uorescence intensities in the absence and presence of a quencher, respectively; K SV is the SternVolmer quenching constant and [Q] is the quencher concentration. The K SV can be determined using the linear regression of the plot of F 0 /F against [Q], as shown in Fig. 1(b) . The calculated K SV values at 298, 304, and 310 K are summarized in Table 1 . The K SV values decreased with increasing temperature, which indicated that the quenching of HSA by MOXH was initiated by complex formation via the static quenching process rather than dynamic collision.
27
To further substantiate the quenching mechanism, uores-cence lifetime measurements were performed. Fig. 2 depicts the uorescence decay of HSA in the absence and presence of MOXH. Evidently, the uorescence decay proles almost remained unchanged aer the addition of MOXH at three different concentrations. The corresponding data were analyzed using tail tting method, and the goodness of t was assessed by c 2 values. The average uorescence lifetime (s) was calculated based on the decay time and the relative amplitude (a) by using the following equation:
As presented in Table 2 , the binding of MOXH did not cause an evident decrease in the s values. In general, a decrease in the mean decay time of the entire excited-state population should be attributed to dynamic quenching; static quenching with the ground-state complex formed has almost no effect on the decay time of the uncomplexed uorophores.
28,29 Therefore, the static quenching mode between MOXH and HSA was further conrmed.
Binding constants and the number of binding sites
For static quenching, the binding constant (K a ) and the number of binding sites (n) can be determined by plotting the doublelogarithm regression curve of the uorescence data with the modied Stern-Volmer equation:
K a and n values were obtained from the intercept and slope of the curve of log[( Fig. 1(c) ], and were summarized in Table 1 . All values of n were approximately equal to one, which indicated that a single high-affinity binding site existed in HSA. Moreover, MOXH exhibited a relatively strong affinity to HSA according to the K a values (10 5 magnitude).
Thermodynamic parameters and the nature of the binding forces
Four non-covalent interaction forces, including hydrogen bond, van der Waals (VDW) force, hydrophobic force, and electrostatic Table 1 Stern-Volmer quenching constants, binding parameters, and thermodynamic parameters of MOXH-HSA system at different temperatures
Stern-Volmer quenching constants Binding parameters Thermodynamic parameters interactions, promote small molecules binding to biological macromolecules. 30 To characterize the binding force involved in MOXH-HSA, the thermodynamic parameters such as enthalpy change (DH), entropy change (DS), and Gibbs free energy change (DG), were calculated according to the van't Hoff equations:
where K a is the binding constant at the corresponding temperature (T), and R is the gas constant. DH and DS values were obtained from the slope and intercept of the linear plot ln K a versus 1/T based on eqn (6) [ Fig. 1(d) ], and DG values were estimated from eqn (7) at corresponding temperatures ( Table  1 ). The negative values for DG indicated that the binding of MOXH to HSA occurred spontaneously. The negative DH suggested that the binding reaction was an exothermic process, thereby providing a reasonable explanation for the decreasing K a in Table 1 . Besides, the negative values of DH and DS demonstrated that hydrogen bonds and VDW force were the main forces governing binding in the MOXH-HSA system, according to the theory of Ross and Subramanian. UV-vis spectroscopy. UV-vis spectroscopy is a simple and intuitive approach to investigating the structural changes in protein-ligand interactions, similar to uorescence spectra. The UV-vis spectra of HSA with various concentrations of MOXH were shown in Fig. 3(a) . The absorption peak of HSA at about 280 nm increased with gradual addition of MOXH and a distinct red shi (from 279 nm to 287 nm) was observed. This phenomenon indicated that MOXH bound to HSA which caused conformational changes of HSA, and thus the hydrophobicity around the aromatic amino acid residues increased. 33 When Dl between excitation and emission wavelengths is stabilized at 15 and 60 nm, shis in the maximum emission of the synchronous uorescence reect the changes in polarity around the tyrosine (Tyr) and tryptophan (Trp) residues of HSA, respectively. 34 Fig. 3(b) and (d) exhibit the synchronous uo-rescence spectra of MOXH-HSA system. The uorescence intensity of HSA regularly decreased with addition of MOXH, which revealed the occurrence of uorescence quenching during the binding process consistent with uorescence data above. Furthermore, no shi occurred in the maximum emission wavelength at Dl ¼ 15 nm whereas a slight blue shi at Dl ¼ 60 nm was observed. This phenomenon indicated that the MOXH binding affected the conformation of HSA and lead to an increase in hydrophobicity around the Trp residues, which was in line with the UV-vis result. 12, 24 To further clarify the secondary structural changes in HSA by MOXH, 3D and CD spectra studies were conducted.
3.4.3. 3D uorescence spectroscopy. 3D uorescence spectroscopy is known to provide detailed information regarding to the conformation of protein.
35 Fig. 4 displays the 3D uorescence spectra of HSA with and without MOXH. The related spectra parameters are listed in Table 3 . As shown in Fig. 4 , peak a represents the Rayleigh scattering peak (l ex ¼ l em ). Peak I exhibits the spectral behavior of Trp and Tyr residues, corresponding to the microenvironment polarity; peak II mainly reveals the polypeptide backbone structures of HSA. 36 Aer the addition of MOXH, the uorescence intensity of both peaks I and II showed an evident decrease. Furthermore, blue shi was observed both in peak I (4 nm) and peak II (7 nm). These ndings indicated that binding with MOXH changed the conformation of HSA, and led to an decrease in polarity surrounding the Trp and Tyr residues.
3.4.4. CD spectroscopy. CD spectroscopy is a reliable and sophisticated method to analyze the secondary structure change of protein aer ligand binding. 37 The CD spectra of HSA in the absence and presence of MOXH exhibited two negative bands at 208 nm and 222 nm as shown in Fig. 3(c) , which indicates the dominance of the typical a-helix structure. 24 The data were further analyzed by the algorithm SELCON3, 38 and the fractions of a-helix, b-sheet, turn, and unordered coil were listed in Table 4 . The free HSA comprised 46.3% a-helix, 14.0% bsheet, 16.9% turn, and 25.4% unordered coil. Aer addition of MOXH, the a-helix content increased whereas the b-sheet and turn content decreased. When the molar ratio of MOXH to HSA reached 2.5 : 1, the a-helix, b-sheet and turn were changed to 55.1%, 7.8%, 15.6%, respectively. Thus, the interaction of MOXH and HSA altered the secondary structure of HSA. And the original bonding of HSA, which is necessary to form secondary and tertiary protein structures, was affected when MOXH inserted into HSA.
Site marker displacement studies
HSA is a globular protein that contains three homologous helical domains (I, II, and III), and each domain can be divided into two subdomains (A and B). 39 Crystal structure analysis indicated that there are two major and structurally selective binding sites called Sudlow site I and Sudlow site II in HSA, which are located in subdomains IIA and IIIA, respectively.
40
To investigate the possible binding sites of MOXH, site marker displacement studies were conducted using phenylbutazone and ibuprofen as sites I and II probes, respectively. 41 The percentage of displacement (I) by a site marker can be calculated as follows:
where F 2 and F 1 are the uorescence intensities of MOXH-HSA in the presence and absence of site markers, respectively. The plot of I values against the molar ratio of probe to HSA is shown in Fig. 5 . The uorescence intensity decreased remarkably with increasing phenylbutazone concentration, whereas a negligible effect was observed with ibuprofen addition. These results suggested that MOXH and phenylbutazone shared the same binding site thereby phenylbutazone competed with MOXH. Thus, MOXH was mainly bound to site I in subdomain IIA of HSA.
Molecular docking studies
Molecular docking studies provide some insights into the interaction between small molecule and biomacromolecule. In the present study, molecular docking was performed to further identify the exact binding site of MOXH on HSA and promote visual understanding of the binding site. As shown in Fig. 6(a 
Conclusions
Multi-spectroscopic methods and computational simulations were applied to explore the binding characteristics, interaction mode, and conformational changes of MOXH with HSA. The uorescence spectroscopy demonstrated that MOXH interacted with HSA through the complex formation via static mechanism, which was proved by time-resolved uorescence. According to uorescence data, binding of MOXH to HSA was relatively strong with binding constants (K a ) of 10 5 L mol À1 . The calculated thermodynamic parameters indicated that hydrogen bonds and van der Waals force were the major elements to drive the MOXH-HSA binding. The UV-vis spectra, synchronous uorescence, and 3D uorescence results suggested that binding with MOXH changed the conformation of HSA, and increased the hydrophobicity around the Trp residues. The secondary structure of HSA was affected by the MOXH-HSA binding; an increase in a-helix content whereas a decrease in bsheet and turn content of HSA were induced in binding process, considering the CD data. Site marker displacement experiments revealed that MOXH mainly bound to site I in subdomain IIA of HSA. The molecular docking results suggested the site I binding mode, which coincides well with the experimental results. Molecular dynamics simulations further corroborated the reliability of the docking results, and provided a more reasonable conformation of the MOXH-HSA complex. Six hydrogen bonds formed between MOXH and residues (Glu 153, Ser 192, Arg 218, and Arg 222) of HSA, together with the VDW force and hydrophobic force, played major roles in stabilizing the MOXH-HSA complex. All these results indicated that MOXH could steadily bind to site I of HSA. This study might contribute to a better understanding of binding mechanism of MOXH with HSA, and help to comprehend the dynamic equilibrium process of drugprotein interaction.
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